TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04385277

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo BM aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo BM biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dinutuximab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FDG-Positron Emission Tomography
Description: Undergo FDG-PET

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Iobenguane I-123
Description: Undergo 123I-MIBG

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Given SC or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO or via enteral tube
Study: NCT00468104

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo in 100 cc of normal saline was instilled intrapleurally daily for three days
Study: NCT04625387

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry Needle and Exercise
Description: A 0.25 X 15 mm acupuncture needle was used for sub occipital muscle and 0.25 X 40 mm needle was used for paraspinal and trapezius muscle. All the necessary precautions were maintained before inserting the needle. Therapists wore hand gloves for all purposes.~The exercise for the muscles of cervical group, for group A was carried out by elevating head from lying in supine position repeating 20 times in three sets and pressing a theraband forward in one set of 15 repetitions, to right side and to left side and back side

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry Needle and Exercise
Description: A 0.25 X 15 mm acupuncture needle was used for sub occipital muscle and 0.25 X 40 mm needle was used for paraspinal and trapezius muscle. All the necessary precautions were maintained before inserting the needle. Therapists wore hand gloves for all purposes.~The exercise for the muscles of cervical group, for group A was carried out by elevating head from lying in supine position repeating 20 times in three sets and pressing a theraband forward in one set of 15 repetitions, to right side and to left side and back side
Study: NCT03518827

Intervention type: OTHER
Intervention: Asymmetry measurement
Description: There is no intervention, the study will prospectively assess associations between asymmetries and injury risk. Asymmetry measurement will be conducted, then injuries will be tracked.
Study: NCT02814201

Intervention type: BEHAVIORAL
Intervention: SRT
Description: simple reaction time ( SRT) defined as the fastest response time to a target stimulus ( phase worst -off at the Parkinson's patient )

Intervention type: BEHAVIORAL
Intervention: SRT
Description: simple reaction time ( SRT) defined as the fastest response time to a target stimulus ( phase worst -off at the Parkinson's patient )

Intervention type: BEHAVIORAL
Intervention: SRT
Description: simple reaction time ( SRT) defined as the fastest response time to a target stimulus ( phase worst -off at the Parkinson's patient )

Intervention type: BEHAVIORAL
Intervention: SRT
Description: simple reaction time ( SRT) defined as the fastest response time to a target stimulus ( phase worst -off at the Parkinson's patient )
Study: NCT01245985

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: carbon ion boost
Description: patients receive induction chemotherapy with TPF for a maximum of 3 cycles followed by radioimmunotherapy with cetuximab as intensity-modulated radiotherapy (IMRT) plus carbon ion boost
Study: NCT03170999

Intervention type: OTHER
Intervention: Focus group interview
Description: Focus group interviews will take place to discuss the key domains of COPD exacerbation which then will be used in the formation of the draft item set.

Intervention type: OTHER
Intervention: Draft item set
Description: Items that form the draft item set will be subject to cognitive debriefing. Questions in the draft item set will collect information on whether the subjects with COPD have experienced that item during an exacerbation. Changes in this draft set will result in the formation of candidate item set.

Intervention type: OTHER
Intervention: Candidate item set
Description: Item reduction will be done using candidate item set and the subjects will be asked to respond to the candidate items on a 4-point scale in terms of how that item changed with the onset of the last episode. Item reduction will take into account frequency and magnitude of items, floor and ceiling items and consistency between regions. The candidate item set will then be used for generation of CERT.
Study: NCT04589949

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ConvP
Description: Infusion of plasma retrieved from donors with a history of PCR proven symptomatic COVID.~Plasma will be administered according to the Erasmus MC KIS protocol regarding the use of blood products

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FFP
Description: Infusion of thawed non-convalescent plasma Plasma will be administered according to the Erasmus Medical Center quality protocol regarding the use of blood products
Study: NCT03028220

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dexcom G5 Continuous Glucose Monitor
Description: Real time continuous glucose sensor connected to monitor providing data and alarms and alerts for glucose trends and values

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Abbott Freestyle Libre
Description: Continuous glucose recording device which reports glucose concentration and trend on demand, along with a retrospective review of the last 8 hours glucose data
Study: NCT04156854

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Quantitated Blood Volume Analysis
Description: Measurement of total blood volume, composed of red blood cell mass (RBCM) and plasma volume (PV) by administering low dose iodinated I-131 labeled albumin intravenously then taking blood samples at timed increments.
Study: NCT02723526

Intervention type: OTHER
Intervention: Blood drawing
Study: NCT03191773

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Drugs and anti-CD19 CAR transduced T cells
Description: Drug: Fludarabine On days -4 through -2, Fludarabine 30mg/m2 (IV) will be infused over 30 minutes.~Drug: Cyclophosphamide On days -4 through -2, Cyclophosphamide 300-500mg/m2 IV will be infused over 60 minutes followed by fludarabine.~Biological: Anti-CD19-CAR T cells On day 0, cells will be infused intravenously IV over 20 - 30 minutes.
Study: NCT00262951

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interferon alfa
Description: administered subcutaneously (SQ)at a dose of 3 million units Day 1,3, and 5 each week in Cycle 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: administered at a dose of 30 mg/m2 intravenously (IV) day 1 each week in Cycle 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: administered at a dose of 175 mg/m\^2/day continuous infusion (CI) for 38 days in Cycle 1 and then 500 mg/m\^2 intravenously (IV) each week for 6 weeks followed by a 2 week rest (1 cycle = 8 weeks)in Cycle 2 and 3

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: 5040 cGy total, in 28 fractions, at 180 cGy/fraction daily, Monday -Friday, for 5½ weeks (days 1-5, 8-12, 15-19, 22-26, 29-33, 36-38).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection of tumor
Description: After Cycle 1 treatment (if resectable)- In the absence of metastatic disease, special emphasis will be paid to the local tumor. Evaluation of the growth/regression of the tumor will be made as it relates to resectability. Surgical exploration will start with a diagnostic laparoscopy. If no evidence of carcinomatosis, liver metastases or other evidence of metastatic disease is encountered, then a laparotomy will be performed. In the absence of clear technical unresectability, a radical pancreaticoduodenectomy, distal or total pancreatectomy (and resection of any involved structures) will be performed as mandated by tumor anatomy.
Study: NCT01227382

Intervention type: PROCEDURE
Group type: OTHER
Intervention: ERCP with cholangiopancreatoscopy
Description: Endoscopic Retrograde Cholangiopancreatography (ERCP)with cholangiopancreatoscopy and sampling of stricture with SpyBite biopsy forceps, cytology brush and RJ3biopsy forceps
Study: NCT03085615

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Jevity 1.5
Description: Jevity 1.5 is an enteral nutrition product delivering 1.5 kcals/mL and 0.06 g protein/mL.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jevity 1.5
Description: Jevity 1.5 is an enteral nutrition product delivering 1.5 kcals/mL and 0.06 g protein/mL.
Study: NCT02825030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coppertone (BAY 987516)
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.(Formulation-SR15-78_Y73-167).
Study: NCT01863576

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3
Description: The group omega-3 receives 5 capsules / day, each capsule containing 1100mg of lipids, and 600 mg of omega-3, 3g of omega-3 per day (1.8 g EPA and 1.2 g DHA) for a period of 8 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: The group placebo receives 5 capsules / day of corn oil containing 1100mg each, for a period of 8 weeks.
Study: NCT03452579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 240mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: 240mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Dose Bevacizumab
Description: 10mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose Bevacizumab
Description: 3mg/kg
Study: NCT05396482

Intervention type: DIAGNOSTIC_TEST
Intervention: Pure tone audiometer
Description: Pure tone audiometer
Study: NCT03561831

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: propofol based anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: sevoflurane based anesthesia
Study: NCT01506609

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Study: NCT04226885

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fentanyl
Description: nebulized fentanyl 2μg/kg body weigh

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: midazolam
Description: nebulized midazolam 0.2 mg/kg body weight 30 min before surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidine
Description: nebulized dexmedetomidine 2 μg/kg body weight 30 min before surgery.
Study: NCT03922646

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurocognitive Empowerment for Addiction Treatment (NEAT)
Description: NEAT will be conducted in person, in groups of 6-14, and consist of 14, 1.5-hour sessions. Each NEAT session will consist of (1) a didactic, psychoeducation portion describing the concepts and skills of focus, (2) written material with descriptions of the concepts/skills in verbal and pictorial (cartoon) formats, (3) practicing with cognitive tasks relevant for each skill, (4) discussion of how they can monitor and practice each skill in their daily life. Specifically, we will provide psychoeducation, cognitive exercises, time-management and daily practice focused on domains of attention (focused and divided attention; attentional biases), memory (declarative, prospective, emotional memory), flexibility and inhibition, and problem-solving. Each session will discuss the relevance of these functions for the recovery from drug addiction and for managing affective/motivational symptoms commonly related to substance use (i.e., craving, anxiety, depression, trauma).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Description: The active control intervention will be composed of active, but non-essential aspects of the larger treatment program (i.e., those that treatment programs do not believe are necessary or central to their program, for example, art classes, exercise classes, chore time, or extra 12 steps meetings). This will ensure that subjects are not being prevented from accessing treatment that is already known to be helpful in substance use recovery, that the active control condition and NEAT intervention have equivalent credibility and expectancies, and optimizing the generalizability of findings.
Study: NCT01777451

Intervention type: OTHER
Intervention: Additional imaging or surgery
Description: No specific intervention is necessary. If a suspicious lesion is diagnosed on MRI, further investigation will be planned (PET-CT or surgery - biopsy)
Study: NCT02962960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anifrolumab
Description: subcutaneous administration every 2 weeks from week 0 to week 50

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anifrolumab
Description: subcutaneous administration every 2 weeks from week 0 to week 50

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: subcutaneous administration every two weeks from week 0 to week 50

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: subcutaneous administration every two weeks from week 0 to week 50
Study: NCT02276183

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutrition intervention, test formula

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: progressive physical activity
Description: Tai Chi; dynamic strength training (knee extension, knee flexion, hip extension, side leg raise, plantar flexion); flexibility warm up and cool down (shoulder and upper arm stretch, hamstrings stretch, calf stretch, ankle stretch); aerobic fitness training(walking on even flat ground); balance training(standing on one foot; heel-to-toe walk; toe stand)
Study: NCT00912301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium chenodeoxycholate (NaCDC)
Description: 500 or 1000 milligrams NaCDC per day each for a period of 4 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium chenodeoxycholate (NaCDC)
Description: 500 or 1000 milligrams NaCDC per day each for a period of 4 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules with identical appearance to the study drug were prepared by the Mayo Clinic research pharmacy.
Study: NCT01532895

Intervention type: DRUG
Intervention: Hydromorphone HCI OROS
Description: type= exact number, unit= mg, number=4, form= tablet, route= oral use. One tablet administered once a day. The dose may be increased if the level of pain increases or if the pain-killing effect is insufficient.
Study: NCT02534454

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Retraining

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Retraining

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sham Retraining

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sham Retraining
Study: NCT02020265

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EEG neurofeedback

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EEG neurofeedback

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: EEG neurofeedback
Study: NCT03727217

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pre and postoperative ultrasound
Description: An ultrasound is performed in preoperative and in postoperative
Study: NCT03090360

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Infant formula (CF)
Description: Formula-fed infants will be randomly assigned to receive one of the study formulas (CF or EF) orally, ad libitum, each day from Study Day 1 until Study Day 180, for a treatment duration of approximately 180 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Infant Formula (EF)
Description: Formula-fed infants will be randomly assigned to receive one of the study formulas (CF or EF) orally, ad libitum, each day from Study Day 1 until Study Day 180, for a treatment duration of approximately 180 days.
Study: NCT00360841

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Auricular acupuncture
Description: Subjects will be randomized to one of these arms. The subjects in arm A and B will receive auricular acupuncture. Before subjects receive chemotherapy within one day, they will be treated by auricular acupuncture, sham acupuncture, or control group.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Auricular acupuncture
Description: Subjects will be randomized to one of these arms. The subjects in arm A and B will receive auricular acupuncture. Before subjects receive chemotherapy within one day, they will be treated by auricular acupuncture, sham acupuncture, or control group.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sham auricular acupuncture

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham auricular acupuncture
Study: NCT02956395

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Integrated care intervention
Description: Integrated care intervention is implemented by a multidisciplinary team from the hospital and from the Primary Care.~The intervention after hospital discharge a) Phone call at 24 hours; b) Home visit at 72 hours after discharge by one member of the transitional care team, if is needed; During this visit, the therapeutic plan for each patient will be customized to their individual frailty factors and shared with the primary care team. Reinforcement of the logistics for treatment of co-morbidities and social support will be done accordingly; c) Accessibility to the point of care available 24 hours/day ; d) Accessibility to the individualized PHF, as self-management tool ; d) appointment at 1m after discharge and after 12 m
Study: NCT02744053

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dynamic Contrast-Enhanced Magnetic Resonance Imaging
Description: Undergo DCE-MRI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Scintimammography
Description: Undergo MBI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technetium Tc-99m Sestamibi
Description: Given via injection
Study: NCT03789669

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cheetah femtosecond laser and Cheetah patient interface
Description: Ophthalmic laser surgical system

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IntraLase iFS iFS femtosecond laser and patient interface
Description: Commercial ophthalmic laser surgical system

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cheetah femtosecond laser and cheetah patient interface
Description: Ophthalmic laser surgical system
Study: NCT04206124

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Brown Fat Harvest During Anterior Neck Surgery
Description: During previously indicated thyroid gland removal or anterior cervical spine surgery, as scheduled at UNMHSC, the surgeon will identify the large muscle on the side of the neck in the surgical field. Using minimal dissection adjacent to the muscle, they will then remove 5-10mg of brown fat from this region. These samples will be further analyzed using various biochemical tools.
Study: NCT02534454

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active transcranial direct current stimulation (TDCS)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active transcranial direct current stimulation (TDCS)
Study: NCT04080635

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Venapuncture
Description: Blood samples will be collected to determine the serum trough levels and anti-drug antibodies of brodalumab

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient questionnaires
Description: The study participant will complete the Dermatology Quality of Life Index (DLQI) and EQ5D5L
Study: NCT04033926

Intervention type: DRUG
Group type: OTHER
Intervention: KZR-616
Description: Subcutaneous 30 mg weekly for 2 weeks, then 45 mg weekly for 14 weeks

Intervention type: DRUG
Group type: OTHER
Intervention: KZR-616
Description: Subcutaneous 30 mg weekly for 2 weeks, then 45 mg weekly for 14 weeks

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Subcutaneous injection for 16 weeks

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Subcutaneous injection for 16 weeks
Study: NCT01578447

Intervention type: DRUG
Group type: OTHER
Intervention: DepoSubQ Provera 104 in Uniject
Description: DepoSubQ Provera 104 in Uniject

Intervention type: DRUG
Group type: OTHER
Intervention: Intramuscular DMPA
Description: Intramuscular DMPA
Study: NCT02258737

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transitional Case Management
Description: The case management activity deals with organizational and clinical aspects. The objective is to focus on network's expectations during hospitalization and at discharge, and ensure contacts between hospital and patient' social network. The aim is to support patient during the transition phase following discharge

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Routine hospitalization care is broadly defined as the usual level of care in the context of the adult department of psychiatry of the CHUV (Centre Hospitalier Universitaire Vaudois).
Study: NCT00581308

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GORE® HELEX® Septal Occluder
Description: Percutaneous transcatheter closure of ostium secundum atrial septal defects (ASDs)